The Potency Chains Of Events For mRNA/LNP Therapeutics

By Steve Wolk, Ph.D., founder and chief consultant, Sinawali Biotechnology Solutions

Defining Potency And The Therapeutic Index

Two related but distinct critical parameters for any drug are the potency and the therapeutic index (TI). Potency is a measure of the amount of a drug required to produce a specific, desired effect of a given intensity. The therapeutic index, on the other hand, is the ratio between the toxic dose and the effective dose of the drug (TD₅₀/ED₅₀). This ratio defines the therapeutic window, which is the range of doses over which the drug achieves therapeutic efficacy for most of the population while maintaining acceptably low toxicity.

Of course, any set of conditions that alter the concentration and ratios of the key components of a therapeutic will affect the potency and may also generate impurities that may increase toxicity. Broadly, two major potency chains govern the efficacy of therapeutics. The first is the manufacturing and distribution chain, often referred to as the cold chain, which determines whether the drug product that reaches the patient is the same as the one that existed at the end of the manufacturing process. The second is the in vivo biological chain, which is an exquisitely complex sequence of events that begins at administration and ends, in the case of mRNA/LNP therapeutics, with correct protein expression inside target cells that leads to the desired phenotypic expression.

Understanding these chains, and where they are most vulnerable, is essential not only for improving current therapies but for scaling RNA medicines into durable, global platforms.

Chain One: The Manufacturing And Cold Chain Path

The first potency chain begins long before a therapeutic encounters a human body. It starts at manufacturing and extends through storage, transportation, and inventory management until the product is administered to the patient.

In simplified form, this chain often looks like:

Manufacturer → Distributor → Wholesaler → Pharmacist → Patient

During each step and at each handoff, the therapeutic is potentially exposed to conditions that can negatively impact potency, as discussed above. Opportunities for impact to product quality and mitigation steps are discussed in detail below.

Key Environmental Stressors

Several environmental factors are known to affect mRNA/LNP integrity, including:

• Temperature: The mRNA, the lipid components as well as the LNP structure are all temperature sensitive. mRNAs (and gRNAs in the case of CRISPR applications) are susceptible to backbone hydrolysis, depurination, oxidation of the bases, and hydrolytic deamination,^6,14 and the rates generally increase with increasing temperature. Elevated temperatures, as well as freeze/thaw cycles, can accelerate lipid hydrolysis and oxidation, as well alter the dynamic structure of the LNPs, causing fusion/fission, aggregation, changes in the polydispersity index (PDI) and membrane rupture/cargo leakage.⁹
• Light exposure: mRNA is susceptible to photodegradation, including the formation of uridine dimers (which can result in cross-linking) and uracil and/or cytosine hydrates, as well as chain cleavage.²⁹ Certain lipid components and excipients can undergo photooxidation, leading to chemical instability and potentially toxic degradation products.
• Air (oxidation) exposure: All non-closed manufacturing steps, including filling or vial access steps, create exposure to air and therefore oxidation. As discussed above, RNA bases are susceptible to oxidation, particularly guanosine. The amines present in the ionizable lipids (iLipids) are also prone to oxidation (-NH₂ > -NHR > -NR₂).
• Moisture: For lyophilized products, residual moisture content is a critical determinant of long-term stability. Depending on local buffer and metal concentrations,¹⁹ degradation pathways such as iLipid hydrolysis and LNP aggregation can be activated.^20,24
• Contamination exposure: Particulates, microbial contamination, or adventitious nucleases can irreversibly compromise potency and facilitate immune responses in patients. Residual metals can also catalyze the hydrolysis of mRNA.

Critical Control Points

To preserve potency across this chain, developers must understand not only what can go wrong, but where it is most likely to occur. The goal is not simply regulatory compliance, but potency predictability; confidence that the therapeutic delivered to a patient retains the functional characteristics established during development. Important stages for monitoring and characterization include:

Manufacturing steps

• Preparation and handling of nucleic acids (gRNA, mRNA, and templates)
• Lipid Manufacture
  • Impurity profiles of the lipids must be carefully monitored. A famous example published by Moderna²² showed that an aldehyde impurity in an ionizable lipid (iLipid) covalently modified the mRNA and inhibited translation, and none of biophysical analytics of formulated LNP formulation detected it.
• LNP assembly and encapsulation
  • LNP formation and % encapsulation is sensitive to total lipid concentration, lipid-to-nucleic acid ratios (N/P ratio), and mixing rates (total flow rate and flow rate ratio)¹⁸
• Filtration, filling, and sealing processes
  • LNP size and PDI are particularly sensitive to shear forces within the tangential flow filtration (TFF) steps.⁸

Storage

• Long-term and accelerated stability studies are needed to define acceptable temperature and humidity ranges.
• Ongoing environmental monitoring in storage facilities ensures that drug substance and drug product are maintained within acceptable ranges.

Transportation

• Stability studies that simulate real-world transit conditions are needed to validate shipping conditions.
• Continuous temperature and shock monitoring during shipment help ensure product quality.

Inventory management

• First-expiry-first-out (FEFO) controls are implemented to minimize product aging/expiry.
• Monitoring of storage excursions at pharmacies or clinical sites is used to ensure product quality

Analytical Methodologies

Validated analytical methods are needed to assess all of parameters discussed here meaningfully. Standard assays include:

• mRNA Integrity
  • ion paring reverse phase ultra performance liquid chromatography (IP-RP-UPLC), capillary electrophoresis (CE), agarose gels
• gRNA Integrity
  • IP-RP-UPLC-MS (IP-RP-UPLC-mass spectrometry)
• Lipid Integrity
  • UPLC-MS
• LNP Structural Integrity (size, PDI, surface charge, shape, blebbing)
  • Dynamic light scattering (DLS), zeta potential, cryogenic electron microscopy (cryo-EM), asymmetrical field flow fractionation (AF₄), transmission electron microscopy (TEM)
• % Encapsulation
  • fluorescence (e.g., Ribogreen)

It should be noted that small modifications to RNA such as base oxidation can be very challenging to detect and quantitate by LC-MS due to the similarity of the impurities to the unmodified compound.

Chain Two: The In Vivo Potency Chain

While the manufacturing and cold chain determine whether a therapeutic arrives to the patient intact, the in vivo chain determines whether it arrives at the target cells in a functional form. The in vivo chain is wonderfully complex and intricate, involving layers of biology that are still being actively deciphered.

Circulation And Early Fate

Once administered, LNPs immediately encounter a dynamic biological environment, involving protein corona formation, biodistribution, and clearance. These early steps can either facilitate delivery to target tissues or divert particles to clearance degradation pathways.

• Protein corona formation: Plasma proteins rapidly adsorb to the LNP surface, altering its identity and physical properties, which influencing downstream interactions.  
• Biodistribution and Clearance: The corona, lipid composition, and particle size collectively shape where the LNP travels and which tissues it reaches. LNPs preferentially accumulate in the liver, driven by interaction with apolipoprotein E (ApoE), which drives targeting of hepatocytes via the low-density lipoprotein receptor (LDLR).¹⁰ Person-to-person differences in plasma chemistry (e.g., genetic variation, disease vs. normal, etc.) may influence the protein corona composition and therefore may change the biodistribution. The optimum particle size also differs from species to species due to differences such as the structure of the fenestrae in the liver,¹² and may impact the interpretation of pre-clinical animal studies.

Cellular Uptake And Intracellular Processing

Reaching a tissue does not guarantee success at the cellular level. LNPs must then navigate:

• Endocytosis: Uptake pathways vary by cell type (e.g., receptor types, receptor density, recycle rates), and can influence uptake rates and intracellular fate.
• Endosomal escape: Endosomal escape is one of the most critical but inefficient steps in steps leading to expression, and is currently estimated at 1-10%.^4,15 Most endocytosed LNPs are guided to lysosomes and degraded. Approaches to enhance endosomal escape include iLipid structure, structural variants of cholesterol and phospholipids, addition of modifiers (e.g., proteins/peptides, cell penetrating peptides (CPPs), endolytic small molecules), and viral structure mimics. ^{1,4,5,11,17,21} If endosomal escape is too strong, (e.g., endosomal rupture), this can potentially trigger immune response, shutdown of translation, cell death, etc., and therefore reduce potency.
• Intracellular sequestration: Even escaped cargo may be trapped in non-productive compartments such as RNA granules.²⁶
• Degradation: RNA can be degraded, both chemically and enzymatically within endosomes, the cytoplasm, or during prolonged sequestration, though developing analytics to assess these events individually will be challenging.

Each of these steps represents a potential bottleneck where potency can be dramatically reduced.

Translation Efficiency

Successful cytoplasmic release is still not the end of the chain. For mRNA therapeutics, potency ultimately depends on protein translation, and even phenotypic expression beyond that. Important steps in the translation process include:

• Transport of mRNA to ribosomes
• Interaction with endogenous translation regulation mechanisms
• Expression of full-length, correctly folded protein
• Appropriate post-translational processing, if required

Even small inefficiencies at any of these steps can disproportionately affect therapeutic output.

Immune Activation As A Cross-Cutting Modifier

Immune responses intersect with nearly every step of the in vivo chain. Potential impacts to potency include:

• Opsonization in circulation can accelerate clearance.
• Innate immune activation can alter cellular uptake and/or cause suppression of the translation machinery.

Managing immune activation is therefore not just a safety concern, but a core determinant of potency.

Additional Complexity For CRISPR-Based mRNA/LNP Therapeutics

For CRISPR-based mRNA/LNP therapies, the in vivo chain extends even further. Beyond translation, additional steps are required:

• Formation of the ribonucleoprotein (RNP) in the cytoplasm
• Nuclear transport of the RNP via nuclear localization signals (NLS)
• Chromatin unwinding at the target locus
• Precise cleavage at the intended genomic site vs. other similar sites in the genome (off-target editing).

Each added step compounds the probability of failure and may underscore why genome editing efficiency often appears low despite robust delivery.

The Engineering Perspective: Why Success Is Remarkable

When viewed end-to-end, the number of events required for an mRNA/LNP therapeutic to succeed is staggering. From cold chain integrity to chromatin accessibility in CRISPR applications, the system depends on dozens of coordinated processes, many of which evolved for entirely different biological purposes.

That these therapies work at all is a testament to both biological robustness and decades of engineering innovation. Clinical and real-world data now make it clear that the pathway does work but also that small improvements at multiple key bottlenecks can yield outsized gains in potency.

The Analytics Gap And The Path Forward

Ideally, developers would have quantitative analytics at each step of both potency chains. In the manufacturing chain, this is increasingly achievable through advanced characterization, real-time monitoring, and digital tracking.

In the in vivo chain, however, analytics remain limited. While tools exist to measure biodistribution, protein expression, and immune activation, many intermediate steps, such as endosomal escape efficiency or intracellular sequestration, are still inferred rather than directly measured. The lack of stepwise measurements can lead to misinterpretation of data during therapeutic development. For example, a contaminant (e.g., dsRNA) can activate an immune response, which may then signal the cell to slow protein expression, which is then misinterpreted by researchers to mean the LNP formulation was not very potent.

Encouragingly, the science continues to advance. New imaging methods, reporter systems, and molecular probes are beginning to illuminate previously opaque steps. As these tools mature, they will enable more rational engineering of RNA/LNP systems, allowing developers to identify and reinforce weak links rather than relying on empirical iteration alone.

Conclusion

Potency in mRNA/LNP therapeutics is not a single hurdle to overcome but a relay race in which the efficiency at each segment and every handoff matters. From manufacturing and cold chain logistics to intracellular translation and genome editing, each link in the chain must function as intended.

For developers, the implication is clear: potency must be designed, protected, and verified across the entire lifecycle of the therapeutic. Doing so requires not only better materials, but better systems thinking — an appreciation of how physical, chemical, and biological processes intersect to determine clinical outcomes.

As RNA medicines continue to expand into new indications and patient populations, mastery of these potency chains will increasingly define success.

References

1. Chatterjee S, et al. (2024) PNAS 121(11):e2307800120. Endosomal escape: A bottleneck for LNP-mediated therapeutics.
2. Danese J (2020) https://www.birlasoft.com/articles/iot-and-blockchain-the-next-gen-power-combo-for-pharma-cold-chain. IoT and Blockchain: The Next-Gen Power Combo for Pharma Cold Chain.
3. Dowdy S, et al. (2022) Delivery of RNA Therapeutics: The Great Endosomal Escape!
4. Dowdy S (2023) RNA 29(4):396-401. doi: 10.1261/rna.079507.122. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
5. Dowdy (2025) TIDES Presentation, Delivery of RNA Therapeutics: The Great Endosomal Escape!
6. Elzahar NM, et al. (2018) Analytical and Bioanalytical Chemistry 410:3375-3384. Degradation product characterization of therapeutic oligonucleotides using liquid chromatography mass spectrometry.
7. Gao K, et al. (2024) ACS Nano 18(44):30293-30306. Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles.
8. Geng C, et al. (2023) Journal of Controlled Release 364:632-643. A preparation method for mRNA-LNPs with improved properties.
9. Hashiba K, et al. (2024) Communications Biology 7:556. Overcoming thermostability challenges in mRNA–lipid nanoparticle systems with piperidine-based ionizable lipids.
10. Hosseini-Kharat M, et al. (2025) Molecular Therapy Methods & Clinical Development 33(1):101436. Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism.
11. Jia Y, et al. (2024) Adv. Mater. 36(4): 2305300. Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid.
12. Lam K, et al. (2023) Adv. Mater. 35: 2211420. Optimizing Lipid Nanoparticles for Delivery in Primates.
13. Lin C, et al. (2025) Adv. Sci. 12: 2409729. Exceptional Uptake, Limited Protein Expression: Liver Macrophages Lost in Translation of Synthetic mRNA.
14. Lindahl T (1993) Nature 362:709-715. Instability and Decay of the Primary Structure of DNA.
15. Liu H, et al. (2024) Advanced Functional Materials 34(39):240510. Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA/LNP Delivery.
16. Liu K, et al. (2023) Nature Comms 14:4007. Multiomics analysis of naturally efficacious lipid nanoparticle coronas reveals high-density lipoprotein is necessary for their function.
17. Lu RM, et al. (2024) J Biomed Sci 31:89. Current landscape of mRNA technologies and delivery systems for new modality therapeutics.
18. Maeki M (2017) PLoS One 12(11):e0187962. Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers.
19. Molina MdC, Anchordoquy TJ (2007) Biochim Biophys Acta 1768(3): 669–677. Metal Contaminants Promote Degradation of Lipid/DNA Complexes During Lyophilization.
20. Munoz-Moreno R, et al. (2025) npj Vaccines 10:49. A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral response.
21. Oliveras R (2026) Inside Therapeutics: https://insidetx.com/review/endosomal-escape-a-critical-challenge-in-lnp-mediated-therapeutics/. Endosomal Escape: A Critical Challenge in LNP-Mediated Therapeutics.
22. Packer M, et al. (2021) Nature Comms 12:6777. A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems.
23. Sahneh FD, et al (2013) PLOS One 8(5):e64690. Dynamics of Nanoparticle-Protein Corona Complex Formation: Analytical Results from Population Balance Equations
24. Sato M, et al. (2025) Pharmaceutics 17(9):1194. doi: 10.3390/pharmaceutics17091194. Examining the Impact of Storage Conditions on the Stability of a Liquid Formulation of mRNA-Loaded Lipid Nanoparticles.
25. Swingle KL, et al. (2021) Trends in Molecular Medicine 27(6):616-617. Lipid Nanoparticle-Mediated Delivery of mRNA Therapeutics and Vaccines.
26. Thomas MG, et al. (2010) Cell Signal 23(2):324–334. doi: 10.1016/j.cellsig.2010.08.011. RNA granules: The good, the bad and the ugly.
27. Welch AR (2026) Advancing RNA https://www.advancingrna.com/doc/the-monster-under-the-bed-defining-potency-in-the-mrna-space-0001?utm_source=linkedin&utm_medium=social&utm_campaign=ARW+linkedin+posts&utm_id=ARW, The Monster Under The Bed: Defining Potency in the mRNA Space.
28. Wilhelmy C, et al. (2025) J Control Rel 384: 113848. Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: Refining paradigms.
29. Wurtmann EJ, Wolin SL (2009) Crit Rev Biochem Mol Biol. 44(1):34–49. doi: 10.1080/10409230802594043. RNA under attack: Cellular handling of RNA damage.

About The Author:

Steve Wolk, Ph.D., is founder and chief consultant for Sinawali Biotechnology Solutions. He was formerly vice president of chemistry and Boulder site head for Editas Medicine, where he led the advanced technology, analytical sciences & structural biology, and process chemistry teams. In addition to an extensive history directing analytical groups for characterizing oligonucleotides, proteins, small molecules, and polymers, Wolk has led efforts to develop new technologies for delivery of CRISPR therapeutics and worked on an aptamer-based proteomic technology. He received his bachelor’s degree in chemistry from U.C. San Diego, where he received the Harold Urey Award. Wolk completed his Ph.D. work in biophysical chemistry at U.C. Berkeley under Ignacio Tinoco, Ph.D., where he used 2D-NMR and other spectroscopic techniques to characterize nonstandard DNA structures. Wolk also has broad experience in leadership, including management, developing future leaders, and creating/revising governance programs.